EGFR and neoplasm: In these cases, the originally detected activating EGFR mutation (e.g. p.L858R) was always present, while the p.T790M alterations always showed lower VAFs in each case suggesting tumor heterogeneity (5.4-12.2% VAF versus 8.1-88% VAF for activating mutations).